ArticleCellular and molecular life sciences : CMLS2026
RRx-001 ameliorates astrocyte pyroptosis by regulating LCN2-NLRP3 inflammasome activation in an MPTP-induced parkinson's disease mouse model.
Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Parkinson's disease (PD) is characterized by progressive neurodegeneration closely linked to neuroinflammation and oxidative stress-induced damage and is characterized by the loss of dopaminergic (DAergic) neurons and the inflammatory response associated with glial cells. RRx-001 (RRx, 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) is a small-molecule immunoregulator. Recent studies have shown that it strongly inhibits NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome activation, which is crucial for influencing neuroinflammation. However, the mechanism underlying the effect of RRx on PD remains unclear. In this study, we explored the potential effects of RRX on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mice, detected the transcriptome and metabolome of the substantia nigra, and performed 16 S microbial diversity sequencing and metabolomics of the intestinal tract. Our study revealed that RRx obviously relieves MPTP-induced DAergic neuronal loss and motor disorders. Mechanistically, RRx reversed the upregulated expression of lipocalin-2 (LCN2) and NLRP3 inflammasome activation in a PD model. Crucially, its protective effects on DAergic neurons involved improving LCN2-NLRP3 inflammasome activation-mediated astrocyte pyroptosis. RRx also reduced the levels of metabolites and signalling pathways associated with oxidative stress and PD in the substantia nigra. Furthermore, the 16 S rDNA analysis and metabolomic analysis of faecal pellets revealed that the intestinal tract of the RRx-treated PD mice presented a greater abundance of Deferribacterota at the phylum level than that of the PD model mice, and the gut microbiota metabolites and pathways were altered. Overall, the results of this study indicate that RRx has multiple effects on PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.